Drug Trial Radar · NCT00118365
Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps
Last checked: Nov 20, 2026Latest source record: Jan 22, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
375
Actual
Start
Jul 1998
Primary completion
Aug 2008
Study completion Aug 2008
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Jul 11, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized phase III trial is studying eflornithine and sulindac to see how well they work compared to a placebo in preventing colorectal cancer in patients with colon polyps. Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of eflornithine and sulindac may prevent colorectal cancer. It is not yet known whether eflornithine and sulindac are more effective than a placebo in preventing colorectal cancer
Conditions
- Precancerous Condition
Interventions
placeboOther
Given orally
eflornithineDrug
Given orally
sulindacDrug
Given orally
laboratory biomarker analysisOther
Correlative studies
Primary outcomes
What the sponsor says the trial is designed to measure.
- Detection of Any Adenoma at the End of the StudyTime frame: Up to 36 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of California Medical Center At Irvine-Orange Campus
Orange, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.